Abstract 2600
Background
Atezo (anti–PD-L1) is approved for platinum-treated mUC and other indications. Here, we evaluated long-term OS and safety data from IMvigor211, a randomised study evaluating atezo monotherapy vs chemo in platinum-treated mUC (Powles Lancet 2018; primary analysis median follow-up: ≈ 17 mo).
Methods
Pts with disease progression during or following platinum-based chemo were assigned 1:1 to atezo 1200 mg or chemo (vinflunine, paclitaxel or docetaxel per investigator) IV q3w. OS (primary endpoint) and safety were evaluated descriptively in this ad hoc analysis.
Results
As of 8 Nov 2018, median follow-up was 34.3 mo. OS HRs were similar to those from the primary analysis. 24- and 30-mo OS rates were higher with atezo vs chemo in the intent-to-treat (ITT) and PD-L1 populations (Table). In ITT pts, OS HRs with atezo vs taxanes and vinflunine were 0.73 (95% CI: 0.59, 0.90) and 0.90 (95% CI: 0.74, 1.09), respectively. Grade 3-4 treatment-related adverse events (AEs) occurred in 22% of atezo-treated pts and 43% of chemo-treated pts (Grade 5 treatment-related AEs in 1% vs 2%, respectively). AEs leading to treatment discontinuation occurred in 9% of atezo-treated pts and 18% of chemo-treated pts. 11% of atezo-treated patients had a Grade 3-4 AE of special interest (vs 2% with chemo). 29% and 31% of pts in the atezo and chemo arms, respectively, received ≥ 1 subsequent non-protocol therapy; 8% in the chemo arm had non-protocol immunotherapy.Table:
918P OS in IMvigor211 ITT and PD-L1 populations
PD-L1 IC2/3 | PD-L1 IC1/2/3 | ITT | ||||
---|---|---|---|---|---|---|
Chemo n = 118 | Atezo n = 116 | Chemo n = 309 | Atezo n = 316 | Chemo n = 464 | Atezo n = 467 | |
Number of deaths (% of randomised pts) | 97 (82) | 85 (73) | 269 (87) | 261 (83) | 403 (87) | 386 (83) |
Median OS (95% CI), mo | 10.6 (8.4, 12.2) | 11.1 (8.6, 15.4) | 8.2 (7.4, 9.5) | 8.9 (8.2, 10.9) | 8.0 (7.2, 8.6) | 8.6 (7.8, 9.6) |
Stratified HR (95% CI) | 0.87 (0.64, 1.17) | 0.84 (0.70, 1.00) | 0.82 (0.71, 0.94) | |||
24-mo OS rate (95% CI) | 19% | 33% | 14% | 22% | 13% | 23% |
(12, 27) | (24, 42) | (10, 17) | (18, 27) | (10, 16) | (19, 26) | |
30-mo OS rate (95% CI) | 17% | 29% | 10% | 18% | 10% | 18% |
(10, 24) | (21, 38) | (7, 14) | (14, 23) | (7, 13) | (15, 22) |
Data cutoff, 8 Nov 2018. Median follow-up, 34.3 mo (range: 0-42.3). Stratification factors: PD-L1 status on tumour-infiltrating immune cells (IC), chemo type, liver metastases, and number of prognostic risk factors. PD-L1 status on IC evaluated per VENTANA SP142 assay.
Conclusions
In this long-term update from IMvigor211, including 24- and 30-mo OS rates, continued OS benefit in favor of atezo vs chemo was observed in the ITT population and in PD-L1 subgroups. No formal statistical comparisons were performed in this ad hoc analysis. Safety results were consistent with those in the primary analysis.
Clinical trial identification
NCT02302807.
Editorial acknowledgement
Jessica Men, PharmD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
M.S. Van der Heijden: Honoraria (institution), Research grant / Funding (institution): Astellas; Honoraria (institution), Research grant / Funding (institution): BMS; Honoraria (institution), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (institution), Research grant / Funding (institution): AstraZeneca; Honoraria (institution), Travel / Accommodation / Expenses: MSD; Honoraria (institution): Janssen. Y. Loriot: Advisory / Consultancy: Roche. I. Duran: Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: MSD; Advisory / Consultancy: Pharmacyclycs; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Astellas. A. Ravaud: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis. M.M. Retz: Full / Part-time employment: Technical University Munich, Germany. N.J. Vogelzang: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Caris; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Esai; Advisory / Consultancy: Tolero; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Exelixis; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Clovis; Travel / Accommodation / Expenses: SWOG; Travel / Accommodation / Expenses: US Oncology. B. Nelson: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. J. Wang: Advisory / Consultancy, Full / Part-time employment: Roche/GNE. X. Shen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/GNE. T. Powles: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: F. Hoffmann-La Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Travel / Accommodation / Expenses: Exelixis; Honoraria (self), Travel / Accommodation / Expenses: Merck; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Travel / Accommodation / Expenses: Incyte; Honoraria (self), Travel / Accommodation / Expenses: Seattle Genetics.
Resources from the same session
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract
6058 - Level of physical activity and nutritional status in cancer patients with fatigue: an exploratory cross-sectional study
Presenter: Patrick Jahn
Session: Poster Display session 3
Resources:
Abstract
1980 - Catheter related necrotizing fascitiis in haematological patients. Case report and implications for nursing
Presenter: Arianna Rosich Soteras
Session: Poster Display session 3
Resources:
Abstract
3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study
Presenter: Marlene Jensen
Session: Poster Display session 3
Resources:
Abstract
2202 - Scalp cooler is effective in reducing chemotherapy-induced alopecia among breast cancer patients : a single institution experience
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
5942 - Nursing management of fatigue in cancer patients: mixed methods study
Presenter: Angela Tolotti
Session: Poster Display session 3
Resources:
Abstract
2930 - Awareness of Nursing Students about the Warning Signs of Cancer
Presenter: Hatice Yakar
Session: Poster Display session 3
Resources:
Abstract
2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.
Presenter: STYLIANI MICHALOPOULOU
Session: Poster Display session 3
Resources:
Abstract
3400 - Radiation dose variables related to the causes of skin toxicities in women with breast cancer: a study proposal
Presenter: EULALIA PUJOL
Session: Poster Display session 3
Resources:
Abstract
2156 - How should the symptoms be managed after breast cancer surgery? An example of mobile app
Presenter: AYDANUR AYDIN
Session: Poster Display session 3
Resources:
Abstract